Brought to you by 
Invitrogen buys Dynal Biotech for $386mm
10 Feb 2005
Executive Summary
Adding bead-based isolation technologies to its portfolio, Invitrogen is acquiring private company Dynal Biotech ASA (technology for molecular separation and purification) from Nordic Capital (the company's majority shareholder) and a co-investor for about $386mm.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Invitrogen buys Dynal Biotech for $386mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice